Shannon Dahl Email and Phone Number
Shannon Dahl work email
- Valid
- Valid
- Valid
Shannon Dahl personal email
- Valid
Shannon Dahl phone numbers
Driving Therapeutic Innovation from Discovery to CommercializationI am a visionary leader in the biotechnology industry with a longstanding reputation for transforming groundbreaking scientific research into market-ready therapies that save lives. With a strong foundation in scientific strategy and business development, I excel at guiding high-growth biotech companies through the critical phases of development. My unique blend of expertise allows me to navigate the complexities of R&D, regulators, commercialization, and reimbursement – guaranteeing that innovative therapies reach the patients who need them most.Over the course of my executive career, I have gained a holistic understanding of the biotech landscape, from early-stage research to Phase 3 clinical trials and reimbursement, as well as the growth of companies through these stages. My strategic insights have often been the key to securing significant funding, forging strategic partnerships, and building high-performing teams. Whether I’m developing a unified vision for teams to develop new therapies or I’m negotiating value-based care agreements or engaging with a range of critical stakeholders, I bring a forward-thinking approach to every project to drive success at every stage.One of my passions is supporting development of new therapeutics. I balance both a business mindset and a scientific outlook, and I am proud of the skills and areas of expertise I’ve built in my career, including:• R&D Strategy & Operations• Therapeutic Pipeline Strategy & Operations• Clinical Translation, Clinical Endpoints, and KOL Engagement• Payer Relationships and Pathways to Reimbursement • Commercialization • Strategic Partnerships and Fundraising• Executive Leadership and Team Building• Translational Research • Biomanufacturing and GMP ProcessesAs a trusted strategic advisor and board member, I have guided numerous biotech startups to achieve their goals by enabling substantial growth, sparking innovation, and capturing and communicating the value created. I am motivated by a commitment to excellence and a passion for advancing healthcare, and I continuously look for new opportunities to make a meaningful impact. Let's connect and talk about the next wave of biotech innovation. Feel free to reach out to me here on LinkedIn!
Carve Bio
View-
Founder And Chief Executive Officer (Ceo)Carve Bio Oct 2021 - PresentI lead a boutique consulting firm that provides fractional CSO or CSO/CBO roles, strategic consulting, and reimbursement strategy, with a focus on immunology or cell & gene therapy. We serve VC-backed, PE-backed, and public biotech therapeutics companies to guide them through critical development phases and achieve their scientific and commercial objectives.Working fractionally, I maximize value creation by developing innovative product strategies and driving drug development. I navigate complex regulatory and reimbursement landscapes, secure substantial funding, and build strong partnerships that position my clients for long-term success. Through Carve Bio, I have supported numerous high-growth biotech clients – driving their projects from early-stage research and funding through the path to commercialization and reimbursement. -
Chief Scientific OfficerIolyx Therapeutics Jan 2022 - PresentI direct scientific, translational, and strategic initiatives for therapies at the intersection of autoimmunity and ophthalmology, enabling clinical translation of the lead and building a pipeline. -
Expert-In-Residence (Xir)Digitalis Commons Aug 2024 - PresentI advise ARPA-H on how to shape their funding programs, to enable successful translation from transformative R&D to commercialization. -
Strategic AdvisorRadar Therapeutics Oct 2023 - PresentRadar is developing genetic medicines to read the cell’s profile, and to only make medicines in the right cells, at the right time. I advise on development and strategy. -
Strategic AdvisorLaguna Bio Aug 2024 - PresentBerkeley, Ca, Us -
Chief Scientific OfficerLaguna Bio Nov 2023 - Aug 2024Berkeley, Ca, UsContributed to the development of a novel immunotherapy for cancer, designed to activate and expand the immune system by leveraging the evolutionary interplay between microbes and immune cells. I defined translational research and regulatory strategies to facilitate clinical translation into new indications, and shaped the supporting scientific story. -
Strategic Advisory BoardStrand Therapeutics 2019 - PresentBoston, Massachusetts, UsStrand Therapeutics is utilizing synthetic biology to genetically program mRNA, and is initially focused on therapies for cancer treatment. I provided strategic guidance on team growth, and on translational CMC strategies for regulators, enabling therapeutic advancement and company growth. Company raised $97M Series A and initiated first-in-human trial. -
Scientific Advisory BoardHepatx Corporation 2017 - 2024Palo Alto, Ca, UsThis company is dedicated to developing liver regeneration therapies. I advised on R&D, critical attributes of liver cell therapy, and datasets for regulators, which led to a positive FDA Interact Meeting. -
Chief Business AdvisorEpic Bio Feb 2023 - Sep 2023I advised on strategic partnerships and business operations for an innovative epigenetic gene regulation platform, positioning the company for a successful strategic collaboration and further growth after their $55M Series A. -
Interim Chief Scientific Officer4:59 Newco, A 5Am Ventures Company Oct 2021 - Apr 2022Boston, Ma, UsFunctioned as the interim CSO of Diagon Therapeutics, a stealth allogeneic iPSC-derived cell therapy platform company seed funded by 5AM, Qiming, MRL, JDRF T1D Fund, and CCRM. I built high-functioning teams across immunology, computational biology, functional genomics, cell biology, and nonclinical, and defined high priority focus areas and product success criteria. -
Chief Scientific OfficerCell Care Therapeutics 2018 - Aug 2021Monrovia, California, UsMy role included defining a unified scientific, clinical, regulatory, and commercial vision for miRNA exosome therapies that were immune-modulating for inflammation-driven diseases in ophthalmology and pulmonology, and then optimizing scientific and strategic initiatives to advance preclinical programs and scalable manufacturing. I also transformed company culture, built and led high-performing teams, established new strategic relationships, and delivered significant growth through innovation. Under my leadership, the team transformed the company’s vision into reality and advanced our therapeutic pipeline. -
Co-Founder, Leader Of Reimbursement StrategyHumacyte 2014 - 2018Durham, Nc, UsI played a key role in corporate growth for my last several years with the organization – focusing on reimbursement, commercial development, and patent strategy. I advanced the bioengineered blood vessel platform from discovery to Phase 3 trials, securing advantageous regulatory designations, building a robust pipeline, and negotiating value-based reimbursement paths with CMS.My work led to significant funding rounds, including a $150M Series B, and positioned the organization for a successful NASDAQ listing (HUMA), a BLA under active FDA review, and a positive readout on a pipeline Phase 3 clinical study showing superiority over first line therapy. I am so proud of our achievements and the impact we made in regenerative medicine. -
Co-Founder, Vp Technology And Pipeline DevelopmentHumacyte 2012 - 2014Durham, Nc, UsI pioneered technological advancements and pipeline expansion strategies as I advanced innovative initiatives from concept to clinical trials. I led cross-functionally to bring 3 programs into the clinic with successful INDs, and I led 3 additional programs into late preclinical stage development. I represented Humacyte externally in the lay press and and as a speaker at scientific and medical meetings to share our progress.By building strategic alliances and securing non-dilutive funding, I enhanced the clinical and preclinical pipelines, and scaled novel manufacturing systems. By tripling our IP portfolio, I captured the value we created as assets for the company. -
Co-Founder, Senior Director Of Scientific Operations | Principal ScientistHumacyte 2004 - 2012Durham, Nc, UsI built our internal R&D teams, and led all scientific operations and research initiatives. I strengthened scientific operations and research initiatives to improve efficiency and productivity in preclinical development and scalable GMP manufacturing processes. With the R&D team under me, we pioneered major breakthroughs in product development and biomanufacturing to deliver on a clinically meaningful product platform in a novel scalable manufacturing system, enabling GMP production for clinical trials and the efficiency of operations that comes with scale. Leading R&D teams, I fostered a culture of innovation that resulted in breakthrough advancements in therapeutic development. I also led key partnerships for preclinical studies and for expanding manufacturing capabilities to reinforce the company’s scientific leadership and competitive edge. I partnered across functions to align with regulators on designations and data packages for INDs, to empower future achievements and growth. -
Adjunct Faculty, Department Of SurgeryDuke University 2013 - 2018Durham, North Carolina, UsI enjoyed translational medical research in vascular disease, and retrospective analysis of ESRD patient data with the goal of defining the patient journey and treatment costs, in collaboration with clinical colleagues. -
Research In Orthopedic SurgeryHarvard Medical School 1998 - 1999Boston, Ma, UsMy research focused on osteoblast cell phenotype and functional changes with exposure to extracellular matrix, providing insights on the biology of fibrosis.
Shannon Dahl Skills
Shannon Dahl Education Details
-
Massachusetts Institute Of TechnologyConcentration In Economics -
Duke UniversityBiomedical Engineering (Regenerative Medicine) -
The George Washington UniversityBoardroom Ready Corporate Governance For Executive Women In Bio (Adapted From Biogen'S Program)
Frequently Asked Questions about Shannon Dahl
What company does Shannon Dahl work for?
Shannon Dahl works for Carve Bio
What is Shannon Dahl's role at the current company?
Shannon Dahl's current role is Visionary Biotechnology Executive, Chief Scientific Officer, Board Advisor || Driving Innovation from Discovery to Go-to-Market || Offering Expertise in R&D, Commercialization, and Strategic Growth.
What is Shannon Dahl's email address?
Shannon Dahl's email address is sh****@****ail.com
What is Shannon Dahl's direct phone number?
Shannon Dahl's direct phone number is +161239*****
What schools did Shannon Dahl attend?
Shannon Dahl attended Massachusetts Institute Of Technology, Duke University, The George Washington University.
What skills is Shannon Dahl known for?
Shannon Dahl has skills like Biotechnology, Life Sciences, R&d, Cell Culture, Tissue Engineering, Fda, Regenerative Medicine, Strategic Partnerships, Reimbursement, Technology Transfer, Organizational Leadership, Medical Devices.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial